GreenLight Biosciences Holdings announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway.
GreenLight Biosciences Holdings
Equities
GRNA
US39536G1058
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+22.10% | 47.96B | |
+0.72% | 42.45B | |
+43.96% | 41.47B | |
+26.30% | 31.6B | |
+20.85% | 28.63B | |
-4.47% | 28.03B | |
+52.06% | 14.56B | |
+44.93% | 14.14B | |
+2.73% | 12.58B |